StreetInsider.com News Articles

Form 6-K IceCure Medical Ltd. For: Aug 24

Mon, 24 Aug 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26964533.html

Form 6-K IceCure Medical Ltd. For: Aug 24

Mon, 24 Aug 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26964533.html

IceCure Medical signs Netherlands distribution deal with Scovas Medical

Mon, 24 Aug 2026 07:50:16 -0400

IceCure Medical Ltd. (Nasdaq: ICCM) has entered into an exclusive distribution agreement with Scovas Medical for its ProSense® cryoablation systems in the Netherlands, covering breast cancer and interventional oncology applications, according to a company statement.

Under the agreement, Scovas Medical will serve as IceCure's exclusive distributor in the Netherlands for an initial term, with a view toward negotiating a longer-term arrangement. Scovas Medical is an independent medical device distributor based in the Netherlands that serves specialties including interventional radiology and vascular surgery.

The Netherlands is the site of the independent, multicenter randomized THERMAC clinical trial, which evaluated thermal ablation as a treatment

IceCure Medical signs Netherlands distribution deal with Scovas Medical

Mon, 24 Aug 2026 07:50:16 -0400

The Netherlands is the site of the independent, multicenter randomized THERMAC clinical trial, which evaluated thermal ablation as a treatment

IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands

Mon, 24 Aug 2026 07:50:00 -0400

Agreement expands ProSense® commercialization in the Netherlands as cryoablation advances to Phase III in the Netherlands-based independent THERMAC breast cancer cryoablation trial after achieving the highest complete ablation rate among evaluated thermal ablation technologies

CAESAREA, Israel, Aug. 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into an exclusive distribution

IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands

Mon, 24 Aug 2026 07:50:00 -0400

IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands

Mon, 24 Aug 2026 07:50:00 -0400

IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands

Mon, 24 Aug 2026 07:50:00 -0400

West Cancer Center cleared to enroll patients in IceCure breast study

Thu, 20 Aug 2026 08:17:05 -0400

IceCure Medical Ltd. (NASDAQ: ICCM) announced that the Institutional Review Board of West Cancer Center & Research Institute in Germantown, Tennessee, has approved the company's post-marketing ChoICE Study, which evaluates ProSense® cryoablation for low-risk, early-stage breast cancer in patients aged 70 and older.

Patient enrollment is expected to begin in the coming weeks, according to a press release from the Israel-based company. The study is designed to enroll 400 patients across 30 participating sites, which will also serve as active commercial sites offering ProSense® to patients outside the trial.

The study will be led at West Cancer Center by Dr. Richard Gilmore,

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

Thu, 20 Aug 2026 08:10:00 -0400